T. Starzynska, P. J. Marsh, P. F. Schofield, S. A. Roberts, K. A. Myers and P. L. Stern, “Prognostic Significance of 5T4 Oncofetal Antigen Expression in Colorectal Carcinoma,” British Journal of Cancer, Vol. 69, No. 5, 1994, pp. 899-902.
 E. Wrigley, A. T. McGown, J. Rennison, R. Swindell, D. Crowther, T. Starzynska and P. L. Stern, “5T4 Oncofetal Antigen Expression in Ovarian Carcinoma,” International Journal of Gynecological Cancer, Vol. 5, No. 4, 1995, pp. 269-274.
 J. P. Kuebler and A. de Gramont, “Recent Experience with Oxaliplatin or Irinotecan Combined with 5-Fluorouracil and Leucovorin in the Treatment of Colorectal Cancer,” Seminars in Oncology, Vol. 30, No. 4, 2003, pp. 40-46.
 R. Harrop, N. Drury, W. Shingler, P. Chikoti, I. Redchenko, M. W. Carroll, S. M. Kingsman, S. Naylor, A. Melcher, J. Nicholls, H. Wassan, N. Habib and A. Anthoney, “Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given alongside Chemotherapy Induces Potent Immune Responses,” Clinical Cancer Research, Vol. 13, No. 15, 2007, pp. 4487-4494.
 R. Harrop, N. Drury, W. Shingler, P. Chikoti, I. Redchenko, M. W. Carroll, S. M. Kingsman, S. Naylor, R. Griffiths, N. Steven and R. E. Hawkins, “Vaccination of Colorectal Cancer Patients with TroVax Given Alongside Chemotherapy (5-Fluorouracil, Leukovorin and Irinotecan) is Safe and Induces Potent Immune Responses,” Cancer Immunology, Immunotherapy, Vol. 57, No. 7, 2008, pp. 977-986.
 J. P. Braybrooke, A. Slade, G. Deplanque, R. Harrop, S. Madhusudan, M. D. Forster, R. Gibson, A. Makris, D. C. Talbot, J. Steiner, L. White, O. Kan, S. Naylor, M. W. Carroll, S. M. Kingsman and A. L. Harris, “Phase I Study of MetXia-P450 Gene Therapy and Oral Cyclophosphamide for Patients with Advanced Breast Cancer or Melanoma,” Clinical Cancer Research, Vol. 11, No. 4, 2005, pp. 1512-1520.
 E. Elkord, E. M. Alcantar-Orozco, S. J. Dovedi, D. Q. Tran, R. E. Hawkins and D. E. Gilham, “T Regulatory Cells in Cancer: Recent Advances and Therapeutic Potential,” Expert Opinion on Biology Therapy, Vol. 10, No. 11, 2010, pp. 1573-1586.
 S. L. Clarke, G. J. Betts, A. Plant, K. L. Wright, T. M. El-Shanawany, R. Harrop, J. Torkington, B. I. Rees, G. T. Williams, A. M. Gallimore and A. J. Godkin, “CD4 + CD25 + FOXP3 + Regulatory T Cells Suppress Anti-Tumor Immune Responses in Patients with Colorectal Cancer,” PLoS ONE, Vol. 1, No. 1, 2006, p. e129. doi:10.1371/journal.pone.0000129
 E. Elkord, A. Dangoor, D. J. Burt, T. D. Southgate, S. Daayana, R. Harrop, J. W. Drijfhout, D. Sherlock, R. E. Hawkins and P. L. Stern, “Immune Evasion Mechanisms in Colorectal Cancer Liver Metastasis Patients Vaccinated with TroVax (MVA-5T4),” Cancer Immunology, Immunotherapy, Vol. 58, No. 10, 2009, pp. 1657-1667.
 F. C. Thistlethwaite, E. Elkord, R. W. Griffiths, D. J. Burt, A. M. Shablak, J. D. Campbell, D. E. Gilham, E. B. Austin, P. L. Stern and R. E. Hawkins, “Adoptive Transfer of T(reg) Depleted Autologous T Cells in Advanced Renal Cell Carcinoma,” Cancer Immunology, Immunotherapy, Vol. 57, No. 5, 2008, pp. 623-634.
 M. Murai, P. Krause, H. Cheroutre and M. Kronenberg, “Regulatory T-Cell Stability and Plasticity in Mucosal and Systemic Immune Systems,” Mucosal Immunology, Vol. 3, No. 5, 2010, pp. 443-449. X. Zhou, S. L. Bailey-Bucktrout, L. T. Jeker, C. Penaranda, M. Martinez-Llordella, M. Ashby, M. Nakayama, W. Rosenthal and J. A. Bluestone, “Instability of the Transcription Factor Foxp3 Leads to the Generation of Pathogenic Memory T Cells in Vivo,” Nature Immunology, Vol. 10, No. 9, 2009, pp. 1000-1007.
 S. Vendetti, T. S. Davidson, F. Veglia, A. Riccomi, D. R. Negri, R. Lindstedt, P. Pasquali, E. M. Shevach and M. T. De Magistris, “Polyclonal Treg Cells Enhance the Activity of a Mucosal Adjuvant,” Immunology and Cell Biology, Vol. 88, No. 7, 2010, pp. 698-706.
 P. Correale, M. S. Rotundo, M. T. Del Vecchio, C. Remondo, C. Migali, C. Ginanneschi, K. Y. Tsang, A. Licchetta, S. Mannucci, L. Loiacono, P. Tassone, G. Francini and P. Tagliaferri, “Regulatory (FoxP3+) T-Cell Tumor Infiltration is a Favorable Prognostic Factor in Advanced Colon Cancer Patients Undergoing Chemo or Chemoimmunotherapy,” Journal of Immunotherapy, Vol. 33, No. 4, 2010, pp. 435-441.
 F. A. Sinicrope, R. L. Rego, S. M. Ansell, K. L. Knutson, N. R. Foster and D. J. Sargent, “Intraepithelial Effector (CD3+)/Regulatory (FoxP3+) T-Cell Ratio Predicts a Clinical Outcome of Human Colon Carcinoma,” Gastroenterology, Vol. 137, No. 4, 2009, pp. 1270-1279.
 M. E. Lutsiak, R. T. Semnani, R. De Pascalis, S. V. Kashmiri, J. Schlom and H. Sabzevari, “Inhibition of CD4(+)25+ T Regulatory Cell Function Implicated in Enhanced Immune Response by Low-dose Cyclophosphamide,” Blood, Vol. 105, No. 7, 2005, pp. 2862-2868.
 Y. B. Su, S. Sohn, S. E. Krown, P. O. Livingston, J. D. Wolchok, C. Quinn, L. Williams, T. Foster, K. A. Sepkowitz and P. B. Chapman, “Selective CD4+ Lymphopenia in Melanoma Patients Treated with Temozolomide: A Toxicity with Therapeutic Implications,” Journal of Clinical Oncology, Vol. 22, No. 4, 2004, pp. 610-616.
 P. Correale, M. G. Cusi, K. Y. Tsang, M. T. Del Vecchio, S. Marsili, M. L. Placa, C. Intrivici, A. Aquino, L. Micheli, C. Nencini, F. Ferrari, G. Giorgi, E. Bonmassar and G. Francini, “Chemo-Immunotherapy of Metastatic Colorectal Carcinoma with Gemcitabine plus FOLFOX 4 Followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Interleukin-2 Induces Strong Immunologic and Antitumor Activity in Metastatic Colon Cancer Patients,” Journal of Clinical Oncology, Vol. 23, No. 35, 2005, pp. 89
 P. A. Antony, C. A. Piccirillo, A. Akpinarli, S. E. Finkelstein, P. J. Speiss, D. R. Surman, D. C. Palmer, C. C. Chan, C. A. Klebanoff, W. W. Overwijk, S. A. Rosenberg and N. P. Restifo, “CD8+ T Cell Immunity against a Tumor/Self-Antigen is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells,” Journal of Immunology, Vol. 174, No. 5, 2005, pp. 2591-2601.
 J. F. Curtin, M. Candolfi, T. M. Fakhouri, C. Liu, A. Alden, M. Edwards, P. R. Lowenstein and M. G. Castro, “Treg Depletion Inhibits Efficacy of Cancer Immunotherapy: Implications for Clinical Trials,” PLoS One, Vol. 3, No. 4, 2008, p. e1983.
 L. G. de Pillis, W. Gu and A. E. Radunskaya, “Mixed Immunotherapy and Chemotherapy of Tumors: Modeling, Applications and Biological Interpretations,” Journal of Theoretical Biology, Vol. 238, No. 4, 2006, pp. 841-862.